Abstract:RATIONALE & OBJECTIVE The usefulness of measures of neutrophil gelatinase-associated lipocalin in urine or plasma (u/pNGAL) obtained on clinical laboratory platforms for predicting acute kidney injury (AKI) and severe AKI requiring kidney dialysis (AKI-D) has not been fully evaluated. We sought to quantitatively summarize published data to evaluate the value of urinary and plasma NGAL for prediction. STUDY DESIGN Literature-based meta-analysis and individual-study-data meta-analysis of diagnostic studies following PRISMA-IPD guidelines. SETTING & STUDY POPULATIONS Studies of adults investigating AKI, severe AKI, and AKI-D in the setting of cardiac surgery, intensive care, or emergency department care using either urine or plasma NGAL measured on clinical laboratory platforms. SELECTION CRITERIA FOR STUDIES PubMed, Web of Science, Cochrane Library, Scopus and congress abstracts ever published through February 2020 reporting diagnostic test studies of NGAL measured on clinical laboratory platforms to predict AKI. DATA EXTRACTION Individual-study-data meta-analysis was accomplished by providing authors data specifications tailored to their studies and requesting standardized patient-level data analysis. ANALYTICAL APPROACH Individual-study-data meta-analysis utilized a bivariate time-to-event model for interval-censored data from which discriminative ability (area under the receiver operating characteristic curve (AUC)) was characterized. NGAL cutoff concentrations at 95% sensitivity, 95% specificity, as well as optimal sensitivity and specificity were also estimated. Models incorporated as confounders clinical setting and use versus non-use of urine output as a criterion for AKI. A literature-based meta-analysis was also performed for all published studies including those studies for which the authors were unable to provide individual study data analyses. RESULTS We included 52 observational studies involving 13,040 patients. We analyzed 30 datasets for the individual-study-data meta-analysis with 837 AKI events, 304 severe AKI events, and 103 severe AKI-D events for analyses of urine NGAL and 705 AKI events, 271 severe AKI events, and 178 AKI-D events for analyses of plasma NGAL. Discriminative performance was similar in individual-study-data meta-analysis and literature-based meta-analysis. Individual-study-data meta-analysis AUCs for uNGAL were 0.75 (95% CI 0.73-0.76) and 0.80 (0.79-0.81) for severe AKI and AKI-D, respectively; for pNGAL, the corresponding values were 0.80 (0.79-0.81) and 0.86 (0.84-0.86). Cut-off-concentrations at 95% specificity for uNGAL were >580 ng/mL with 27% sensitivity for severe AKI and >589 ng/mL with 24% sensitivity for AKI-D. Corresponding cut-offs for pNGAL were >364 ng/mL with 44% sensitivity and >546 ng/mL with 26% sensitivity, respectively. LIMITATIONS Practice variability on initiation of acute dialysis. Imperfect harmonization of data across studies. CONCLUSIONS Urinary and plasma NGAL concentrations may identify patients at high risk for AKI in clinical research and practice. The reported cut-off concentrations in this study require prospective evaluation.

The utility of serum neutrophil gelatinase‐associated lipocalin level on predicting autosomal dominant polycystic kidney disease progression

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression

Evaluation of serum neutrophil gelatinase‐associated lipocalin in older patients with chronic kidney disease

Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD

Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function

Reduction in NGAL at 48 h predicts the progression to CKD in patients with septic associated AKI: a single-center clinical study

Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease: a Retrospective Study

Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease

Urinary neutrophil gelatinase-associated lipocalin: A potential biomarker for predicting rapid progression of drug-induced chronic tubulointerstitial nephritis.

[Absorption of extractive Radix Paeoniae Alba in rat everted gut sacs and its interaction with P-glycoprotein].

[Study of genetic diversity and spatial structure of the wild soybean (Glycine soja Sieb. & Zucc.) population from the Ekaterinovka in the south of Primorskii krai].

[Examination of cerebrovascular circulation using radioisotopes].

Validation of plasma neutrophil gelatinase–associated lipocalin as a biomarker for diabetes-related acute kidney injury

Predictive value of serum neutrophil gelatinase-associated lipocalin for acute kidney injury in high-risk elderly patients

Neutrophil Gelatinase-associated Lipocalin Predicts Short-term Outcomes in Decompensated Cirrhosis With Acute Kidney Injury

Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Predictive Role of Neutrophil Gelatinase-Associated Lipocaline in Donor-Specific Antibody-Positive and Donor-Specific Antibody-Negative Renal Transplant Patients

Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes

Prediction of Progression in Polycystic Kidney Disease Using the Kidney Failure Risk Equation and Ultrasound Parameters

Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis.

PKD1 Truncating Mutations Accelerate eGFR Decline in Autosomal Dominant Polycystic Kidney Disease Patients